- Record: found
- Abstract: found
- Article: not found
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Emmanuel S Antonarakis
1 ,
Changxue Lu ,
Hao Wang ,
Brandon Luber ,
Mary Nakazawa ,
Jeffrey C Roeser ,
Yan Chen ,
Tabrez A Mohammad ,
Yidong Chen ,
Helen L Fedor ,
Tamara L Lotan ,
Qizhi Zheng ,
Angelo M De Marzo ,
John T Isaacs ,
William B Isaacs ,
Rosa Nadal ,
Channing J Paller ,
Samuel R Denmeade ,
Michael A Carducci ,
Mario A Eisenberger ,
Jun Luo
Sep 11 2014
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of androgen-receptor splice variant 7 messenger RNA (AR-V7) in circulating tumor cells from men with advanced prostate cancer would be associated with resistance to enzalutamide and abiraterone.